Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GCK | P35557 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4384735 | 0.91 | LMNA (0.47) | LMNASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL4380224 | 0.90 | LMNA (0.45) | LMNASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL4385253 | 0.89 | LMNA (0.45) | LMNASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL4380169 | 0.88 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL4381146 | 0.87 | LMNA (0.46) | LMNASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL4387315 | 0.86 | LMNA (0.52) | LMNASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL4395322 | 0.85 | LMNA (0.45) | LMNASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL4386302 | 0.85 | KDM4E (0.48) | LMNASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL4391011 | 0.85 | LMNA (0.54) | LMNASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL13588993 | 0.84 | L3MBTL1 (0.45) | LMNASMN1; SMN2MAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | LMNA 3822/4885SMN1; SMN2 664/4885MAPT 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.